Document ID: chunk:federal_register_of_legislation:F2025L00216:schedule:1:p2
Version: federal_register_of_legislation:F2025L00216
Segment Type: schedule
Provision Reference: sch 1 (pt 2/2)
Character Range: 5278–6348

50  2  5

     1.        Schedule 2, after entry for Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8
    insert:
   Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A)  50  2  5

     1.        Schedule 2, after entry for Fluoxetine
    insert:
   Tablet, dispersible, 20 mg (as hydrochloride)  50  56  2

     1.        Schedule 2, entry for Gliclazide
    insert as first entry:
   Tablet 30 mg (modified release)  50  200  5

     1.        Schedule 2, after entry for Probenecid
         insert:
Progesterone                Capsule 100 mg                                                                                                                                                    50  60  5
Progesterone and estradiol  Pack containing 30 capsules progesterone 100 mg (micronised) and transdermal gel (pump pack) estradiol 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses  50  2   5